BioArctic and Eli Lilly announced a research and collaboration agreement to build a new neurodegeneration candidate. BioArctic will generate the therapy by combining its Braintransporter technology—designed to move drugs across the blood-brain barrier—with an undisclosed Lilly molecule. The collaboration is positioned around generating a new drug candidate and advancing it through translational development, leveraging BioArctic’s delivery platform for CNS access. For Lilly, it provides an additional entry point into neurodegeneration modalities where BBB penetration remains a persistent development bottleneck. The deal underscores how large pharma is leaning on platform partnerships rather than relying exclusively on internal discovery for CNS pipeline expansion. The immediate focus will be on candidate selection and the data package needed to drive subsequent development decisions. BioArctic’s Braintransporter approach continues to attract validation and partner interest as companies look for repeatable mechanisms to improve CNS exposure.